Agomelatine

CAS No:
138112-76-2 Categories: , , ,
  • #LGM Pharma is a Agomelatine CAS# 138112-76-2 API supplier distributor based in the USA. Inquire about DMF, cGMP, price, availability, delivery, purity, and more.
  • #Questions? Call our customer API support number 1-(800)-881-8210.
  • #LGM Pharma offers this active ingredient but not the finished dosage forms.

Product Details:

  • CAS No: 138112-76-2
  • AHFC code:
  • Synonyms: S-20098 S20098
  • ATC Code: N06AX22
  • Chemical Formula: C16H14N2O4
  • Molecular Weight: 243.301
  • Assay/Purity: Typically NLT 98%
  • DrugBank: DB06594
  • SMILES: COC1=CC2=C(C=CC=C2CCNC(C)=O)C=C1
  • InChl: YJYPHIXNFHFHND-UHFFFAOYSA-N
  • PubChem: 82148
  • IUPAC: N-[2-(7-methoxynaphthalen-1-yl)ethyl]acetamide

Additional Details

Indication:
Agomelatine is indicated for the treatment of major depressive episodes in adults.
Pharmacodynamics:
Agomelatine resynchronises circadian rhythms in animal models of delayed sleep phase syndrome and other circadian rhythm disruptions. It increases noradrenaline and dopamine release specifically in the frontal cortex and has no influence on the extracellular levels of serotonin. Agomelatine has shown an antidepressant-like effect in animal models of depression (learned helplessness test, despair test, chronic mild stress) as well as in models with circadian rhythm desynchronisation and in models related to stress and anxiety. In humans, agomelatine has positive phase shifting properties; it induces a phase advance of sleep, body temperature decline and melatonin onset. Controlled studies in humans have shown that agomelatine is as effective as the SSRI antidepressants paroxetine and sertraline in the treatment of major depression
Mode of Action:
The novel antidepressant agent, agomelatine, behaves as an agonist at melatonin receptors (MT1 and MT2) and as an antagonist at serotonin (5-HT)(2C) receptors.
Metabolism:
Hepatic (90% CYP1A2 and 10% CYP2C9).
Toxicity:
General Reference:
Millan MJ, Brocco M, Gobert A, Dekeyne A: Anxiolytic properties of agomelatine, an antidepressant with melatoninergic and serotonergic properties: role of 5-HT2C receptor blockade. Psychopharmacology (Berl). 2005 Feb;177(4):448-58. Epub 2004 Jul 31. Pubmed Hardeland R, Poeggeler B, Srinivasan V, Trakht I, Pandi-Perumal SR, Cardinali DP: Melatonergic drugs in clinical practice. Arzneimittelforschung. 2008;58(1):1-10. Pubmed Racagni G, Riva MA, Popoli M: The interaction between the internal clock and antidepressant efficacy. Int Clin Psychopharmacol. 2007 Oct;22 Suppl 2:S9-S14. Pubmed
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

API’s From Quality Manufacturers:

  • Cost effective materials based on specific requirements
  • Small quantities for initial research and larger development quantities towards product commercialization

 

  • Technical packages, letters of access to filed DMFs
  • Complete assistance in any regulatory filings
  • Top quality GMP certified manufacturers
  • Have necessary regulatory credentials

 

Related YouTube Videos